A design of phase II cancer trials using total and complete response endpoints

Statistics in Medicine

Volumn 24, Issue 20, 2005, Pages 3155-3170

  Lu, Ying ^a,b,c   Jin, Hua ^c,d   Lamborn, Kathleen R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PEKING UNIVERSITY   (China)

Author keywords

Optimal; Phase II trial; Trinomial; Two stage design

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BIOSTATISTICS; CANCER RESEARCH; CLINICAL RESEARCH; CLINICAL STUDY; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; GLIOBLASTOMA; HUMAN; MATHEMATICAL COMPUTING; PROBABILITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE II; GLIOBLASTOMA; HUMANS; MODELS, STATISTICAL; NUMERICAL ANALYSIS, COMPUTER-ASSISTED; RESEARCH DESIGN;

EID: 27144487810     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.2188     Document Type: Article

References (9)

1. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 1989; 10:1-10.
2. Gehan E. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. Journal of Chronic Diseases 1961; 13:346-353.
3. Lin S, Chen T. Optimal two-stage designs for phase II clinical trials with differentiation of complete and partial responses. Communications in Statistics, Part A - Theory and Methods 1998; 29:923-940.
4. Panageas K, Smith A, Gonen M, Chapman P. An optimal two-stage phase II design utilizing complete and partial response information separately. Controlled Clinical Trials 2002; 23:367-379.
5. Jung S, Carey M, Kim K. Graphical search for two-stage phase II clinical trials. Controlled Clinical Trials 2001; 22:367-372.
6. Conaway M, Petroni G. Bivariate sequential designs for phase II trials. Biometrics 1995; 51:656-664.
7. Zee B, Melnychuk D, Dancey J, Eisenhauer E. Multinomial phase II cancer trials incorporating response and early progression. Journal of Biopharmaceutical Statistics 1999; 9(2):351-363.
8. Dent S, Zee B, Dancey A, Hanauske J, Wanders J, Eisenhauer E. Application of a new multinomial phase II stopping rule using response and early progression. Journal of Clinical Oncology 2001; 19(3):785-791.
9. Freidlin B, Dancey J, Korn EL, Zee B, Eisenhauer E. Multinomial phase II trial designs (Letter to the Editor). Journal of Clinical Oncology 2002; 20(2):599.